

# ARGANZ Meeting

8 – 9 March, 2025

Gold Coast Convention & Exhibition Centre

## Saturday 8 March

### 0830-1030 SESSION 1: Opening Plenary

*Chair: Dr Jessica Yang; Moderator: Dr Wayland Wang*

#### Welcome

Dr Jessica Yang

### 0840-0915 Imaging findings of side effects of oncologic therapies in the abdomen

Prof Christine "Cooky" Menias

- Recognize intra-abdominal adverse effects of targeted therapies in relation to underlying principal molecular mechanisms.
- Describe imaging findings of common adverse effects of targeted cancer therapies.
- Review imaging features of adverse effects related to Immunotherapy.

### 0915-0945 Prostate cancer in the MRI era

Prof Clare Tempny

- To understand the Role of MRI in Prostate cancer from detection to staging.
- Overview of PI-RADS and its results in clinical care.
- To learn how MR can guide biopsy and therapy.

### 0945-1015 The indeterminate small liver lesion: when and how to follow up

Prof Yves Menu

- To determine the different clinical scenario and to appreciate the relative risk in each situation
- To examine strengths and weaknesses of imaging methods for the characterization of small liver lesions
- To build an efficient strategy combining imaging, biology and clinical background

1015-1030 Panel Q&A

### 1030-1100 Morning Tea and Industry Exhibition

#### 1100-1230 SESSION 2A: GIT

*Chair: Dr Wayland Wang; Moderator: Dr Chris Allen*

#### IgG4 in the abdomen

Dr Mark Goodwin

- To learn about the common and uncommon patterns of IgG4-related disease in the abdomen and pelvis.
- To learn tips and tricks for differentiating IgG4-related disease from other disease entities.

#### 1100-1230 SESSION 2B: Pelvis and Renal

*Chair: Dr Melanie Seale; Moderator: Dr Sharon Winters*

#### MRI screening for hereditary renal tumors

Dr Sonja Gustafson

- Hereditary conditions that qualify for annual screening and the appearance of kidneys in those with these conditions & their potential lesion appearances at screening & diagnosis.

<b>1125-1145</b>	<b>GI manifestations of vasculitis</b> Dr Katerina Mastrocostas <ul style="list-style-type: none"> <li>- Classification of vasculitides that affect the gastrointestinal tract and their presentation.</li> <li>- Diagnostic pathway for vasculitis involving the gastrointestinal tract.</li> <li>- Imaging manifestations of vasculitis involving the gastrointestinal tract.</li> </ul>	<b>1120-1140</b>	<b>The sinking ship: MRI of the pelvic floor</b> Dr Arjuna Somasundaram <ul style="list-style-type: none"> <li>- Appreciate the utility of dynamic pelvic floor MRI.</li> <li>- Learn what the referrer wants, and what the radiologist should look for.</li> <li>- Understand the fundamentals of how to perform and report these studies.</li> </ul>
<b>1145-1205</b>	<b>Visceral artery dissection</b> Dr John Vedelago <ul style="list-style-type: none"> <li>- To recognise the imaging features of visceral artery dissection in the abdomen.</li> <li>- To understand the distribution and frequency of this pathology.</li> <li>- To incorporate a visceral artery review into our abdominal cross sectional imaging search pattern.</li> </ul>	<b>1140-1220</b>	<b>Rectal cancer: Making a difference with MRI</b> Dr Kirsten Gormly <ul style="list-style-type: none"> <li>- How to get the most from the latest imaging techniques</li> <li>- Staging updates</li> <li>- Can the patient avoid surgery after treatment?</li> </ul>
<b>1205-1220</b>	<b>Cystic lesions of the abdomen</b> Dr Arani Halder <ul style="list-style-type: none"> <li>- Become familiar with common and rare cystic lesions in the abdomen and pelvis.</li> <li>- Understand the differential diagnosis, initial management and follow up of these lesions.</li> </ul>	<b>1220-1230</b>	Panel Q&A
<b>1220-1230</b>	Panel Q&A		
<b>1230-1330</b>	<b>Lunch and Industry Exhibition</b>		
<b>1330-1500</b>	<b>SESSION 3A: Hepatobiliary</b> <i>Chair: Dr Chris McKee; Moderator: Dr Ravinder Dhillon</i>	<b>1330-1500</b>	<b>SESSION 3B: Female Pelvis</b> <i>Chair: Yu Xuan Kitzing; Moderator: Dr Glen Lo</i>
<b>1330-1400</b>	<b>Biliary tumours: Making challenging cases easy</b> Prof Yves Menu <ul style="list-style-type: none"> <li>- To simplify the wide spectrum of biliary tumours</li> <li>- To determine the critical diagnostic and prognostic information required for each tumour</li> <li>- To understand why imaging is the cornerstone to build treatment strategies</li> </ul>	<b>1330-1350</b>	<b>Endometriosis - The modern curse</b> A/Prof Anusch Yazdani <ul style="list-style-type: none"> <li>- To describe the common clinical presentations of endometriosis.</li> <li>- To describe the classification and staging systems of endometriosis</li> <li>- To describe management options for those diagnosed with endometriosis in line with the Australian Clinical Management Guidelines.</li> </ul>
<b>1400-1420</b>	<b>Hépatites sans frontières: the global liver infection quiz</b> Dr James Seow <ul style="list-style-type: none"> <li>- To interactively test your infectious liver disease imaging skills and general geography knowledge</li> </ul>	<b>1350-1410</b>	<b>MRI for endometriosis in the pre-surgical patient</b> Dr Bridget Sutton <ul style="list-style-type: none"> <li>- Scan protocol optimization and systematic reporting.</li> <li>- Presurgical mapping of DIE in anterior, middle and posterior compartments of pelvis.</li> <li>- MRI diagnosis and preoperative assessment of suspected extra pelvic disease eg. diaphragm, anterior abdominal wall, sacral plexus or sciatic nerve.</li> </ul>
<b>1420-1435</b>	<b>Liver ultrasound elastography and fat quantification</b> Dr Paul Simkin <ul style="list-style-type: none"> <li>- The principles of acquiring reliable liver stiffness measurements with US based shear wave elastography, including quality assurance and troubleshooting.</li> <li>- Dealing elastography results that are discordant with the B-mode imaging.</li> <li>- A brief overview of ultrasound fat quantification technology.</li> </ul>	<b>1410-1450</b>	<b>Practical approach female pelvic MRI</b> Prof Christine "Cooky" Menias <ul style="list-style-type: none"> <li>- Discuss indications for Female Pelvic MRI, highlighting patient preparation and imaging protocols.</li> <li>- Illustrate key anatomy and show how to characterize tissues on MRI.</li> <li>- Describe imaging findings of common benign and malignant conditions.</li> </ul>
<b>1435-1450</b>	<b>What's new in HCC surveillance and assessment of treatment response</b> Dr Jessica Yang <ul style="list-style-type: none"> <li>- Find out what's new in HCC surveillance</li> <li>- Find out what's new in the assessment of HCC treatment response</li> <li>- Find out about new LI-RADS updates</li> </ul>	<b>1450-1500</b>	Panel Q&A
<b>1450-1500</b>	Panel Q&A		

<b>1500-1530</b>	<b>Afternoon Tea and Industry Exhibition</b>	
<b>1530-1700</b>	<b>SESSION 4A: Oncology</b> <i>Chair: Dr Paul Beech; Moderator: Dr Cynthia Benny</i>	<b>1530-1700</b> <b>SESSION 4B: Prostate and Bladder Cancer</b> <i>Chair: A/Prof Rajeev Jyoti; Moderator: Dr Sabbir Siddique</i>
<b>1530-1600</b>	<b>Neuroendocrine tumours: Why the radiologist needs to think differently</b> Prof Yves Menu <ul style="list-style-type: none"> <li>- To learn the main features of the evolving nomenclature and the differences between the WHO classification and the commonly used terms</li> <li>- To determine why CT, MRI and PET are complementary methods for detection and staging</li> <li>- To understand the unique treatment strategies and why neuroendocrine neoplasms are different from most other tumours</li> </ul>	<b>1530-1600</b> <b>Prostate MR: The technical stuff including quality assessment</b> Prof Clare Tempny <ul style="list-style-type: none"> <li>- To understand the technical aspects of the 3 key sequences required for PI-RADS v2.1</li> <li>- To learn how to apply a quality review-PI-QUAL</li> <li>- To learn the MRI appearances of benign conditions of the prostate</li> </ul>
<b>1600-1615</b>	<b>DOTATATE-PET for General and GI Radiologists</b> Dr Tom Huang <ul style="list-style-type: none"> <li>- Recognise the physiologic distribution of DOTATATE-PET and common incidentals.</li> <li>- Krenning score and common diagnostic pitfalls.</li> <li>- Basics of Lutetium Theranostics and interpreting post-treatment scans.</li> </ul>	<b>1600-1620</b> <b>Bladder cancer assessment (VI-RADS) and the utility of PET</b> Dr Jash Agraval <ul style="list-style-type: none"> <li>- Understand the utility of MRI in local bladder cancer staging.</li> <li>- Understand the basic schema of VI-RADS and its importance in patient management.</li> <li>- Discuss the utility and indications for FDG PET-CT.</li> </ul>
<b>1615-1630</b>	<b>Tips on cancer staging</b> Dr Divya Mehta <ul style="list-style-type: none"> <li>- Discuss imaging appearances of a few primary abdominal malignancies, review their TNM staging and patterns of spread.</li> </ul>	<b>1620-1650</b> <b>Prostate recurrence reporting and role of MRI in post-focal therapy assessment</b> Prof Clare Tempny <ul style="list-style-type: none"> <li>- To understand current Prostate cancer treatments used for loco-regional disease.</li> <li>- To review the appearance of the prostate gland after therapy</li> <li>- To learn how to identify and report post treatment local recurrence</li> </ul>
<b>1630-1645</b>	<b>RECIST reporting in a nutshell</b> Dr Sally Ayesa <ul style="list-style-type: none"> <li>- Revise the RECIST 1.1 criteria for reporting oncology studies.</li> <li>- Consider how RECIST 1.1 reporting criteria can be used in practice with case examples.</li> </ul>	<b>1650-1700</b> Panel Q&A
<b>1645-1700</b>	Panel Q&A	
<b>1700-1745</b>	<b>Welcome Function and Industry Exhibition</b>	
<b>1900-2300</b>	<b>Meeting Dinner - Isoletto Privé, Level 6, The Star Gold Coast</b>	

## 0830-1030 SESSION 5

*Chair: Dr Numan Kutaiba*

### 0830-0900 **Liver metastases: New trends that are useful in daily practice**

Prof Yves Menu

- To understand the global strategy from detection to treatment
- To learn why the radiologist has a central position in the overall management of liver metastases
- To be aware of the strengths and weaknesses of MRI liver specific contrast media in the staging and follow-up of liver metastases

### 0900-0930 **Bowel obstruction in the gastric bypass patients**

Prof Christine "Cooky" Menias

- Review imaging of Post Roux-Y-Gastric Bypass
- Highlight complications after Gastric Bypass
- Emphasize Imaging features that should not be overlooked

### 0930-1000 **Research discussion and tips to have your article published**

Prof Cooky Menias (Editor in Chief - Radiographics), Prof Yves Menu (Immediate Past Editor in Chief - European Radiology), Dr Gabes Lau (Editor in Chief - JMIRO)

### 1000-1030 **Mendelson Research Prize Presentations**

1000-1010 Prognosticating factors in PET CT and MRI of cervical cancer treated with chemoradiotherapy

Dr Dominic Ku

1010-1020 External validation of a deep learning model for automated lesion detection and bony metastasis classification on PSMA PET-CT in prostate cancer

Dr Minh-Son To

1020-1030 Double-oblique axial T2 imaging during rectal MRI – A case series

Dr Peter Zarzour

## 1030-1100 **Morning Tea and Industry Exhibition**

### 1100-1300 **SESSION 6: Renal MDT**

*Chair: Dr Nick Kenning*

### 1100-1115 **Urologist's approach to renal lesions/incidentalomas**

Dr Chris Tracey (Urologist)

- Appreciate the approach to small renal mass from a urologist's perspective.
- Appreciate the nuances of imaging important for perioperative planning with respect to partial nephrectomy.

### 1115-1125 **SBRT for renal cell cancer**

Dr Andrew Oar (Radiation Oncologist)

### 1125-1135 **Percutaneous ablation for renal cell cancer**

Dr John Grieve (Interventional Radiologist)

### 1135-1150 **Renal contrast enhanced ultrasound - Breaking out of the bubble**

Dr Dean Rabinowitz

- Review the basics of contrast enhanced ultrasound as a technique.
- Review the current approach to diagnosis of cystic and solid renal lesions
- Consider the specific indications where CEUS should be used as an alternative or adjunct to other methods.
- Observe key examples of cystic and solid lesions using CEUS technique.

### 1150-1300 **MDT - Renal**

Dr Arj Somasundaram (Radiologist & Chair), Dr John Grieve (Interventional Radiologist), Dr Andrew Oar (Radiation Oncologist), Dr Chris Tracey (Urologist), Dr Admire Matsika (Pathologist)

- Learn the nuances of RCC management through robust debate and discussion.
- Tips and tricks for imaging RCCs and how to provide added MDT value.
- A showcase of multidisciplinary specialist knowledge.

**1300-1315** **ARGANZ Annual General Meeting**

**1300-1400** **Lunch and Industry Exhibition**

**1400-1600** **SESSION 7**

*Chair: Dr Deepak Prasad; Moderator: Dr Viola Whitaker*

**1400-1405** **Mendelson Research Prize Announcement**

Dr Won Kyung Sung

**1405-1445** **Cases from the Cooky Jar**

Prof Christine "Cooky" Menias

**1445-1505** **Improving radiology reporting globally and locally: Who, how and why? (And it's not AI)**

Dr Kirsten Gormly

**1505-1515** **Article review - Pancreatic IPMN Kyoto protocol**

Dr Geertje Noe

- Briefly outline of the Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas and its latest revision.
- To become familiar with the latest management algorithm for intraductal papillary mucinous neoplasm.

**1515-1525** **Myth buster #1 - Sorry, this can't be biopsied**

A/Prof Tom Sutherland

- Discuss the breadth of lesions that can be biopsied.
- Discuss the importance of biopsy to guide management and support minimally invasive therapies.
- Discuss which vessels just don't bleed.
- How to evaluate the risk of a radiologist with a needle versus a surgeon with a knife.

**1525-1535** **Myth buster #2 - This dilated CBD is a choledochal cyst**

Dr Mayooraan Kandasamy

- A brief overview of the imaging features, morphology and classification of choledochal cysts.
- Learn about differentiating extrahepatic choledochal cysts from a dilated CBD.

**1535-1545** **Myth buster #3 - You can't give gad in renal failure**

Dr Matthew Aitken

- Understand the safety profile of gadolinium-based contrast agents (GBCAs) and their use in patients with renal failure.
- Differentiate between high-risk and low-risk GBCAs and their implications for nephrogenic systemic fibrosis (NSF).
- Apply current guidelines to safely administer GBCAs in patients with impaired renal function.

1545-1555 Panel Q&A

**1555-1600** **Closing remarks**

Dr Jessica Yang